Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 24Gastrointestinal 11Sarcoma 8Dermatologic 8Thoracic 7Genitourinary 7Breast 7Gynecologic 6Lymphoid 4Endocrine 4CNS 4Other solid neoplasm 3Other hematologic neoplasm 3NET 2Myeloid 2Plasma cell 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1349Leukemia, Myeloid, Acute 1133Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Leukemia 675Precursor Cell Lymphoblastic Leukemia-Lymphoma 646Myeloproliferative Disorders 527Leukemia, Myelomonocytic, Chronic 424Lymphoma, Non-Hodgkin 407Primary Myelofibrosis 384Multiple Myeloma 369Leukemia, Lymphocytic, Chronic, B-Cell 367Hodgkin Disease 348Leukemia, Myeloid, Chronic-Phase 304Lymphoma 291Blast Crisis 256Leukemia, Myeloid, Accelerated Phase 238Lymphoma, Mantle-Cell 231Lymphoma, Follicular 226Burkitt Lymphoma 224Polycythemia Vera 222Lymphoma, Large B-Cell, Diffuse 219Lymphoma, B-Cell, Marginal Zone 203Congenital Abnormalities 192Anemia, Refractory, with Excess of Blasts 187Lymphoma, Large-Cell, Immunoblastic 182Myelodysplastic-Myeloproliferative Diseases 175Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 173Thrombocythemia, Essential 167Neoplasms, Plasma Cell 161Hematologic Neoplasms 161

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Adenoid Cystic × Myeloid × Clear all
NCT03886831 2023-03-28

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Prelude Therapeutics

Phase 1 Completed
232 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Carcinoma, Adenoid Cystic, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled
BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡